Correction: VExUS score: optimizing its use in perioperative and critical care management - Summary - MDSpire

Correction: VExUS score: optimizing its use in perioperative and critical care management

  • By

  • Pierre-Grégoire Guinot

  • July 3, 2026

  • 0 min

Share

Objective:

Correction of author name in the original article.

Key Findings:
  • The author's name was incorrectly transposed in the original publication.
Interpretation:

The correct author name is Pierre-Grégoire Guinot.

Conclusion:

The author group has been updated to reflect the correct name.

Sources:

Original Source(s)

Correction: VExUS score: optimizing its use in perioperative and critical care management

  • by Pierre-Grégoire Guinot

  • July 3, 2026

Related Content

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min
JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a review of mechanisms and clinical evidence

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min